BNB Plus Corp.

BNB Plus Corp. is a company that integrates a digital asset treasury strategy focused on the BNB token with the commercialization of nucleic acid production technologies. Headquartered in Stony Brook, New York, USA, its mission is to provide institutional-grade access to the Binance ecosystem through a transparent, actively managed BNB treasury, while also maintaining its biotechnology operations.

The company's core business encompasses two main segments. Its digital asset treasury segment manages BNB tokens, aiming to generate yield through various strategies within the Binance ecosystem, including native BNB staking, Binance Launch Pool, PancakeSwap LP, and collateralized DeFi strategies. Concurrently, through its LineaRx, Inc. subsidiary, BNB Plus Corp. operates in the biotechnology sector, commercializing the proprietary LineaDNA platform for cell-free DNA production, which serves biopharmaceutical and diagnostics markets.

Under the leadership of President and CEO Clay Shorrock and Chief Investment Officer Patrick Horsman, BNB Plus Corp. rebranded from Applied DNA Sciences, Inc. in November 2025 to reflect its strategic pivot towards digital asset management. The company recently secured initial commitments for $4.1 million in strategic financing in May 2026 to bolster its digital asset treasury and support a comprehensive strategic review. It also completed a significant $1.2 million LineaDNA™ order in April 2026, highlighting continued activity in its biotechnology segment. BNB Plus Corp. positions itself as a regulated U.S. vehicle offering exposure to the Binance ecosystem.